“A recent retrospective study of an inception cohort of 403,337 patients newly diagnosed with rheumatoid arthritis, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, lupus, and sarcoidosis found 72% to be prescribed glucocorticoids (52% at age <50 years).28 Use of glucocorticoids was strongly associated with increased rate of fractures, “
So Mispec: People don’t yet realise that ATL1102 will replace steroids to treat inflammation ... The above paragraph shows the indications ATL1102 could treat... Thats why $2 is very possible (Inflammation market in excess of $120 billion)
ANP Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
